A Phase III Study to Evaluate the Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment
收藏DataCite Commons2026-01-22 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012690/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study was to demonstrate the efficacy and safety of omalizumab, compared with placebo, as an add-on to H1 antihistamines (H1AH) therapy in adult patients suffering from Chronic Spontaneous Urticaria (CSU) who remained symptomatic despite H1AH therapy.
提供机构：
Vivli
创建时间：
2026-01-22
